There are 2867 resources available
235P - The impact of body mass index (BMI) on the progression-free survival of CDK4/6 inhibitors in metastatic breast cancer patients (MBC)
Presenter: Mehmet Artac
Session: Poster session 02
236P - Subgroup analysis by disease history and prior treatments of patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1)
Presenter: Javier Cortés
Session: Poster session 02
237P - HER2DX genomic assay in advanced HER2-positive (HER2+) breast cancer treated with T-DM1
Presenter: Fara Brasó-Maristany
Session: Poster session 02
238P - Clinical safety and pharmacokinetics (PK) data of DZD1516, an BBB-penetrant selective HER2 inhibitor for the treatment of HER2-positive metastatic breast cancer
Presenter: Jian Zhang
Session: Poster session 02
239P - Pyrotinib in combination with docetaxel as first-line treatment for HER2-positive metastatic breast cancer (PANDORA): A single-arm, multicenter phase II trial
Presenter: Xiaojia Wang
Session: Poster session 02
240P - Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases
Presenter: Michele Bottosso
Session: Poster session 02
241P - Genomic analysis of plasma cell-free DNA in patients with heavily pretreated HER-2+ metastatic breast cancer (MBC)
Presenter: Kyoungmin Lee
Session: Poster session 02
242P - Investigating the risk of drug-induced interstitial lung disease in patients with metastatic breast cancer treated with antiHER2 regimens through a network meta-analysis approach
Presenter: Lorenza Palmero
Session: Poster session 02
243P - Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer
Presenter: Stefania Morganti
Session: Poster session 02
244P - Eribulin combined with anlotinib for patients with HER2-negative metastatic breast cancer: A single-arm, multicenter, phase II study
Presenter: Yongmei Yin
Session: Poster session 02